Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind placebo-controlled trial of TAP-144-SR (3M) in SBMA (JASMITT-2)
jRCT2091220080Phase 2Completed
- Sponsor
- JASMITT
- Start
- Jan 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal and bulbar muscular atrophy (SBMA) comparing TAP-144-SR (3M) leuprorelin acetate with Placebo (2 arms). Started Jan 2012; status: completed.
02
Drugs
leuprolide
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on jRCT2091220080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220080.